In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Growth

Accenture: Acquisition Of Early-Stage Assets, Bio-Platforms Key To Accelerated Growth

Acquisitions of early-stage assets, biotech platforms and capabilities like AI are the way to faster growth for pharma companies, as Accenture’s Petra Jantzer told In Vivo. However, changing the focus of M&A away from conventional late-stage assets requires significant shifts in corporate and R&D culture.

Business Strategies Deals

Deals Shaping The Medical Industry, July 2022

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.

Commercial Deals

It’s Time To Re-Think How Pharma Engages With HCPs

Pharma's commercial workforce is engaging with its customers in a myriad of new ways, all of them fueled by digital. These efforts must be co-ordinated, and embrace news ways of working if they are to succeed.

Business Strategies Growth

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals

Snapshot: July Highlights

A selection of articles you might have missed from July 2022, including an exploration of this year's top selling drugs, an in depth discussion about how life sciences leadership is changing, as well as a look into AC Immune's Parkinson's research.

Medical Device BioPharmaceutical

Pushing Forward: Venture Capitalist Priorities To Accelerate European Biotech

Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.

Europe VC Playbook

A Delicate Balancing Act: Juggling Multiple Vendors

Costly delays can come from mismanaged clinical trial processes. Consolidation is vital when managing multiple vendors, and study sites, to ensure your team does not drop the ball.

Clinical Trials Research & Development

Pandemic Windfall Upends Status Quo For Top-10 Best-Selling Drugs

This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.

Growth Sales & Earnings

HealthCap’s Steen On Growing Successful Precision Medicine Businesses

Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.

Rising Leaders C-Suite Speaks

Rejuveron CEO Confident About Longevity Biotech Prospects In Troubled Economy

Swiss-based Rejuveron’s diversified platform of longevity biotechs addresses key hallmarks of aging, with the goal of helping people to age better and live longer with reduced burden of age-related diseases. CEO Matthias Steger discusses the firm’s vision and the road ahead.

Growth Rising Leaders

Citeline And Norstella Merge To Provide End-To-End Solutions For Pharma

Publisher’s Spotlight: Citeline, the publisher of In Vivo, is to merge with fellow pharmaceutical solutions provider Norstella.

BioPharmaceutical Medical Device

Snapshot: June Highlights

A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.

New Science Market Intelligence
See All